Just been reading through the Appendix 4D and Half Year Financial Report released on the 29 Feb 2008 10:12Page 2811. NET TANGIBLE ASSET BACKING31.12.07$1.31
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%